earnings
confidence high
sentiment positive
materiality 0.70
Alpha Cognition Q2 net loss $2.1M; FDA approves ZUNVEYL for Alzheimer's
Alpha Cognition Inc.
2024-Q2 EPS reported
-$0.05
- Q2 2024 net loss $2.1M ($0.01/share) vs Q2 2023 net loss $2.8M ($0.03/share).
- Cash and equivalents $1.0M at June 30, 2024; no revenue reported.
- R&D expenses $0.9M in Q2, down from $1.3M YoY on trial completion.
- FDA approved ZUNVEYL (benzgalantamine) for mild-to-moderate Alzheimer's disease.
- G&A expenses rose to $1.2M in Q2, including $2.3M shares for services under Spartan Capital agreement.